Nature Search

Structural insights into chemoresistance mutants of BCL-2 and their targeting by stapled BAD BH3 helices

Resistance mutations in BCL-2 reduce the clinical efficacy of venetoclax. DeAngelo et al. show stapled BAD BH3 peptides can retain and even enhance binding to these mutants, offering a structurally informed strategy to overcome this mechanism of cancer drug resistance.

Thomas M. DeAngelo
Utsarga Adhikary
Loren D. Walensky
ResearchOpen Access29 Sept 2025
Nature Communications

Volume: 16, P: 1-15
Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial

In a phase 1 trial of patients with advanced systemic mastocytosis, avapritinib, a selective KIT inhibitor, was generally well tolerated, elicited durable clinical responses and led to reductions in mast cell disease burden.

Daniel J. DeAngelo
Deepti H. Radia
Jason Gotlib
ResearchOpen Access06 Dec 2021
Nature Medicine

Volume: 27, P: 2183-2191
Experimental demonstration of logical magic state distillation

Magic state distillation is achieved with logical qubits on a neutral-atom quantum computer using a dynamically reconfigurable architecture for parallel quantum operations.

Pedro Sales Rodriguez
John M. Robinson
Sergio H. Cantú
Research14 Jul 2025
Nature

Volume: 645, P: 620-625
Chromosome 5q deletion and epigenetic suppression of the gene encoding α-catenin (CTNNA1) in myeloid cell transformation

Ting Xi Liu
Michael W Becker
A Thomas Look
Research10 Dec 2006
Nature Medicine

Volume: 13, P: 78-83
Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial

In a prespecified interim analysis of a pivotal phase 2 trial, avapritinib, a selective KIT inhibitor, elicited robust clinical and molecular responses, was generally well tolerated and led to improved patient-reported outcomes in patients with advanced systemic mastocytosis.

Jason Gotlib
Andreas Reiter
Daniel J. DeAngelo
ResearchOpen Access06 Dec 2021
Nature Medicine

Volume: 27, P: 2192-2199
Design and characterization of bivalent BET inhibitors

Targeting the acetyllysine ‘reader’ activity of BET family transcriptional coactivators has emerged as an anticancer modality. A new class of dimeric JQ1 derivatives displays enhanced potency for bivalent targeting of tandem bromodomains in BET proteins.

Minoru Tanaka
Justin M Roberts
James E Bradner
Research24 Oct 2016
Nature Chemical Biology

Volume: 12, P: 1089-1096
Quality of life and mood of older patients with acute myeloid leukemia (AML) receiving intensive and non-intensive chemotherapy

Areej El-Jawahri
Gregory A. Abel
Joseph A. Greer
Research28 Mar 2019
Leukemia

Volume: 33, P: 2393-2402
HSP90 inhibition leads to degradation of the TYK2 kinase and apoptotic cell death in T-cell acute lymphoblastic leukemia

K Akahane
T Sanda
A T Look
Research12 Aug 2015
Leukemia

Volume: 30, P: 219-228
Clinical, pharmacokinetic and pharmacodynamic data for the MEK1/2 inhibitor pimasertib in patients with advanced hematologic malignancies

F Ravandi
A Pigneux
B D Smith
CorrespondenceOpen Access11 Dec 2015
Blood Cancer Journal

Volume: 5, P: e375

Search

Structural insights into chemoresistance mutants of BCL-2 and their targeting by stapled BAD BH3 helices

Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial

Experimental demonstration of logical magic state distillation

Chromosome 5q deletion and epigenetic suppression of the gene encoding α-catenin (CTNNA1) in myeloid cell transformation

Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial

Design and characterization of bivalent BET inhibitors

Quality of life and mood of older patients with acute myeloid leukemia (AML) receiving intensive and non-intensive chemotherapy

HSP90 inhibition leads to degradation of the TYK2 kinase and apoptotic cell death in T-cell acute lymphoblastic leukemia

Clinical, pharmacokinetic and pharmacodynamic data for the MEK1/2 inhibitor pimasertib in patients with advanced hematologic malignancies

Search

Quick links

Search

Filter By:

Search

Quick links